Do analysts recommend HCWB or VIVS?

HCW Biologics currently has a consensus price target of $5.00, indicating a potential upside of 323.73%. Given HCW Biologics' stronger consensus rating and higher probable upside, analysts clearly believe HCW Biologics is more favorable than VivoSim Labs. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score HCW Biologics 1 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00 VivoSim Labs 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Is HCWB or VIVS more profitable?

HCW Biologics has a net margin of -34.73% compared to VivoSim Labs' net margin of -861.27%. VivoSim Labs' return on equity of -15.51% beat HCW Biologics' return on equity. Company Net Margins Return on Equity Return on Assets HCW Biologics -34.73% -486.87% -29.19% VivoSim Labs -861.27% -15.51% -11.31%

Do analysts prefer ERNA or VIVS?

Ernexa Therapeutics currently has a consensus price target of $30.00, suggesting a potential upside of 341.18%. Given Ernexa Therapeutics' stronger consensus rating and higher possible upside, research analysts plainly believe Ernexa Therapeutics is more favorable than VivoSim Labs. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Ernexa Therapeutics 1 Sell rating(s) 1 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00 VivoSim Labs 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Do analysts rate SNGX or VIVS?

Soligenix currently has a consensus price target of $6.00, suggesting a potential upside of 1,305.15%. Given Soligenix's stronger consensus rating and higher possible upside, equities research analysts clearly believe Soligenix is more favorable than VivoSim Labs. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Soligenix 1 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00 VivoSim Labs 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Is SNGX or VIVS more profitable?

Soligenix has a net margin of 0.00% compared to VivoSim Labs' net margin of -861.27%. VivoSim Labs' return on equity of -15.51% beat Soligenix's return on equity. Company Net Margins Return on Equity Return on Assets Soligenix N/A -244.73% -131.22% VivoSim Labs -861.27% -15.51% -11.31%

Do analysts recommend PHIO or VIVS?

Phio Pharmaceuticals currently has a consensus target price of $14.00, suggesting a potential upside of 1,196.30%. Given Phio Pharmaceuticals' stronger consensus rating and higher possible upside, research analysts plainly believe Phio Pharmaceuticals is more favorable than VivoSim Labs. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Phio Pharmaceuticals 1 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00 VivoSim Labs 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Do analysts recommend KPRX or VIVS?

Kiora Pharmaceuticals currently has a consensus target price of $10.00, indicating a potential upside of 286.10%. Given Kiora Pharmaceuticals' stronger consensus rating and higher possible upside, research analysts plainly believe Kiora Pharmaceuticals is more favorable than VivoSim Labs. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Kiora Pharmaceuticals 1 Sell rating(s) 1 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00 VivoSim Labs 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

VivoSim Labs (VIVS) Competitors

$1.19 0.00 (0.00%)

Closing price 04:00 PM Eastern

Extended Trading

$1.18 -0.01 (-1.26%)

As of 04:10 PM Eastern

Compare

VIVS vs. HCWB, ERNA, SNGX, PHIO, and KPRX

Should you buy VivoSim Labs stock or one of its competitors? MarketBeat compares VivoSim Labs with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with VivoSim Labs include HCW Biologics (HCWB), Ernexa Therapeutics (ERNA), Soligenix (SNGX), Phio Pharmaceuticals (PHIO), and Kiora Pharmaceuticals (KPRX). These companies are all part of the "pharmaceutical products" industry.

How does VivoSim Labs compare to HCW Biologics?

HCW Biologics (NASDAQ:HCWB) and VivoSim Labs (NASDAQ:VIVS) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their dividends, valuation, analyst recommendations, media sentiment, institutional ownership, risk, profitability and earnings.

HCW Biologics has a beta of 2.21, indicating that its stock price is 121% more volatile than the broader market. Comparatively, VivoSim Labs has a beta of 1.38, indicating that its stock price is 38% more volatile than the broader market.

3.0% of HCW Biologics shares are owned by institutional investors. Comparatively, 8.2% of VivoSim Labs shares are owned by institutional investors. 9.1% of HCW Biologics shares are owned by insiders. Comparatively, 2.5% of VivoSim Labs shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

In the previous week, HCW Biologics and HCW Biologics both had 1 articles in the media. HCW Biologics' average media sentiment score of 0.80 beat VivoSim Labs' score of 0.00 indicating that HCW Biologics is being referred to more favorably in the media.

Company	Overall Sentiment
HCW Biologics	Positive
VivoSim Labs	Neutral

HCW Biologics currently has a consensus price target of $5.00, indicating a potential upside of 323.73%. Given HCW Biologics' stronger consensus rating and higher probable upside, analysts clearly believe HCW Biologics is more favorable than VivoSim Labs.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
HCW Biologics	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
VivoSim Labs	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

HCW Biologics has a net margin of -34.73% compared to VivoSim Labs' net margin of -861.27%. VivoSim Labs' return on equity of -15.51% beat HCW Biologics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
HCW Biologics	-34.73%	-486.87%	-29.19%
VivoSim Labs	-861.27%	-15.51%	-11.31%

VivoSim Labs has lower revenue, but higher earnings than HCW Biologics. VivoSim Labs is trading at a lower price-to-earnings ratio than HCW Biologics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
HCW Biologics	$6.59M	1.21	-$7.96M	-$9.46	N/A
VivoSim Labs	$140K	22.19	-$2.48M	-$3.15	N/A

Summary

HCW Biologics beats VivoSim Labs on 9 of the 15 factors compared between the two stocks.

How does VivoSim Labs compare to Ernexa Therapeutics?

Ernexa Therapeutics (NASDAQ:ERNA) and VivoSim Labs (NASDAQ:VIVS) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their valuation, institutional ownership, analyst recommendations, dividends, earnings, profitability, risk and media sentiment.

VivoSim Labs has higher revenue and earnings than Ernexa Therapeutics. VivoSim Labs is trading at a lower price-to-earnings ratio than Ernexa Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Ernexa Therapeutics	N/A	N/A	-$14.08M	-$26.20	N/A
VivoSim Labs	$140K	22.19	-$2.48M	-$3.15	N/A

70.6% of Ernexa Therapeutics shares are held by institutional investors. Comparatively, 8.2% of VivoSim Labs shares are held by institutional investors. 0.5% of Ernexa Therapeutics shares are held by company insiders. Comparatively, 2.5% of VivoSim Labs shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

In the previous week, Ernexa Therapeutics had 2 more articles in the media than VivoSim Labs. MarketBeat recorded 3 mentions for Ernexa Therapeutics and 1 mentions for VivoSim Labs. Ernexa Therapeutics' average media sentiment score of 0.00 equaled VivoSim Labs'average media sentiment score.

Company	Overall Sentiment
Ernexa Therapeutics	Neutral
VivoSim Labs	Neutral

Ernexa Therapeutics currently has a consensus price target of $30.00, suggesting a potential upside of 341.18%. Given Ernexa Therapeutics' stronger consensus rating and higher possible upside, research analysts plainly believe Ernexa Therapeutics is more favorable than VivoSim Labs.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Ernexa Therapeutics	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
VivoSim Labs	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Ernexa Therapeutics has a beta of 2.47, meaning that its stock price is 147% more volatile than the broader market. Comparatively, VivoSim Labs has a beta of 1.38, meaning that its stock price is 38% more volatile than the broader market.

Ernexa Therapeutics has a net margin of 0.00% compared to VivoSim Labs' net margin of -861.27%. VivoSim Labs' return on equity of -15.51% beat Ernexa Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Ernexa Therapeutics	N/A	-263.74%	-151.16%
VivoSim Labs	-861.27%	-15.51%	-11.31%

Summary

Ernexa Therapeutics beats VivoSim Labs on 8 of the 14 factors compared between the two stocks.

How does VivoSim Labs compare to Soligenix?

Soligenix (NASDAQ:SNGX) and VivoSim Labs (NASDAQ:VIVS) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their institutional ownership, dividends, media sentiment, earnings, profitability, analyst recommendations, valuation and risk.

Soligenix has a beta of 1.84, suggesting that its stock price is 84% more volatile than the broader market. Comparatively, VivoSim Labs has a beta of 1.38, suggesting that its stock price is 38% more volatile than the broader market.

Soligenix currently has a consensus price target of $6.00, suggesting a potential upside of 1,305.15%. Given Soligenix's stronger consensus rating and higher possible upside, equities research analysts clearly believe Soligenix is more favorable than VivoSim Labs.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Soligenix	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
VivoSim Labs	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

VivoSim Labs has higher revenue and earnings than Soligenix. VivoSim Labs is trading at a lower price-to-earnings ratio than Soligenix, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Soligenix	N/A	N/A	-$11.08M	-$1.68	N/A
VivoSim Labs	$140K	22.19	-$2.48M	-$3.15	N/A

In the previous week, Soligenix had 1 more articles in the media than VivoSim Labs. MarketBeat recorded 2 mentions for Soligenix and 1 mentions for VivoSim Labs. Soligenix's average media sentiment score of 0.00 equaled VivoSim Labs'average media sentiment score.

Company	Overall Sentiment
Soligenix	Neutral
VivoSim Labs	Neutral

Soligenix has a net margin of 0.00% compared to VivoSim Labs' net margin of -861.27%. VivoSim Labs' return on equity of -15.51% beat Soligenix's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Soligenix	N/A	-244.73%	-131.22%
VivoSim Labs	-861.27%	-15.51%	-11.31%

3.6% of Soligenix shares are owned by institutional investors. Comparatively, 8.2% of VivoSim Labs shares are owned by institutional investors. 3.1% of Soligenix shares are owned by insiders. Comparatively, 2.5% of VivoSim Labs shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Summary

Soligenix beats VivoSim Labs on 9 of the 14 factors compared between the two stocks.

How does VivoSim Labs compare to Phio Pharmaceuticals?

Phio Pharmaceuticals (NASDAQ:PHIO) and VivoSim Labs (NASDAQ:VIVS) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their risk, analyst recommendations, institutional ownership, valuation, dividends, earnings, media sentiment and profitability.

Phio Pharmaceuticals has a beta of 0.82, suggesting that its stock price is 18% less volatile than the broader market. Comparatively, VivoSim Labs has a beta of 1.38, suggesting that its stock price is 38% more volatile than the broader market.

57.3% of Phio Pharmaceuticals shares are held by institutional investors. Comparatively, 8.2% of VivoSim Labs shares are held by institutional investors. 0.9% of Phio Pharmaceuticals shares are held by insiders. Comparatively, 2.5% of VivoSim Labs shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Phio Pharmaceuticals has a net margin of 0.00% compared to VivoSim Labs' net margin of -861.27%. VivoSim Labs' return on equity of -15.51% beat Phio Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Phio Pharmaceuticals	N/A	-77.34%	-70.87%
VivoSim Labs	-861.27%	-15.51%	-11.31%

Phio Pharmaceuticals currently has a consensus target price of $14.00, suggesting a potential upside of 1,196.30%. Given Phio Pharmaceuticals' stronger consensus rating and higher possible upside, research analysts plainly believe Phio Pharmaceuticals is more favorable than VivoSim Labs.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Phio Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
VivoSim Labs	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

VivoSim Labs has higher revenue and earnings than Phio Pharmaceuticals. Phio Pharmaceuticals is trading at a lower price-to-earnings ratio than VivoSim Labs, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Phio Pharmaceuticals	N/A	N/A	-$8.70M	-$1.38	N/A
VivoSim Labs	$140K	22.19	-$2.48M	-$3.15	N/A

In the previous week, Phio Pharmaceuticals had 1 more articles in the media than VivoSim Labs. MarketBeat recorded 2 mentions for Phio Pharmaceuticals and 1 mentions for VivoSim Labs. Phio Pharmaceuticals' average media sentiment score of 0.00 equaled VivoSim Labs'average media sentiment score.

Company	Overall Sentiment
Phio Pharmaceuticals	Neutral
VivoSim Labs	Neutral

Summary

Phio Pharmaceuticals and VivoSim Labs tied by winning 7 of the 14 factors compared between the two stocks.

How does VivoSim Labs compare to Kiora Pharmaceuticals?

Kiora Pharmaceuticals (NASDAQ:KPRX) and VivoSim Labs (NASDAQ:VIVS) are both small-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their profitability, dividends, risk, earnings, analyst recommendations, valuation, media sentiment and institutional ownership.

Kiora Pharmaceuticals has a beta of -0.4, meaning that its stock price is 140% less volatile than the broader market. Comparatively, VivoSim Labs has a beta of 1.38, meaning that its stock price is 38% more volatile than the broader market.

In the previous week, Kiora Pharmaceuticals and Kiora Pharmaceuticals both had 1 articles in the media. Kiora Pharmaceuticals' average media sentiment score of 0.00 equaled VivoSim Labs'average media sentiment score.

Company	Overall Sentiment
Kiora Pharmaceuticals	Neutral
VivoSim Labs	Neutral

Kiora Pharmaceuticals has a net margin of 0.00% compared to VivoSim Labs' net margin of -861.27%. VivoSim Labs' return on equity of -15.51% beat Kiora Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Kiora Pharmaceuticals	N/A	-59.30%	-41.23%
VivoSim Labs	-861.27%	-15.51%	-11.31%

77.0% of Kiora Pharmaceuticals shares are held by institutional investors. Comparatively, 8.2% of VivoSim Labs shares are held by institutional investors. 0.1% of Kiora Pharmaceuticals shares are held by insiders. Comparatively, 2.5% of VivoSim Labs shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

VivoSim Labs has higher revenue and earnings than Kiora Pharmaceuticals. Kiora Pharmaceuticals is trading at a lower price-to-earnings ratio than VivoSim Labs, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Kiora Pharmaceuticals	N/A	N/A	-$10.84M	-$2.71	N/A
VivoSim Labs	$140K	22.19	-$2.48M	-$3.15	N/A

Kiora Pharmaceuticals currently has a consensus target price of $10.00, indicating a potential upside of 286.10%. Given Kiora Pharmaceuticals' stronger consensus rating and higher possible upside, research analysts plainly believe Kiora Pharmaceuticals is more favorable than VivoSim Labs.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Kiora Pharmaceuticals	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
VivoSim Labs	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Summary

VivoSim Labs beats Kiora Pharmaceuticals on 7 of the 13 factors compared between the two stocks.

Get VivoSim Labs News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding VIVS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

VIVS vs. The Competition

Export

Metric	VivoSim Labs	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$3.11M	$3.32B	$6.48B	$11.93B
Dividend Yield	N/A	2.31%	2.67%	5.58%
P/E Ratio	-0.38	19.01	24.57	23.75
Price / Sales	22.19	306.41	531.63	116.49
Price / Cash	N/A	51.45	26.99	37.23
Price / Book	0.21	8.20	10.53	6.75
Net Income	-$2.48M	$23.83M	$3.56B	$337.35M
7 Day Performance	-7.03%	-2.68%	-0.88%	-2.45%
1 Month Performance	-14.39%	2.65%	1.45%	1.49%
1 Year Performance	-34.62%	37.85%	21.50%	24.64%

VivoSim Labs Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
VIVS VivoSim Labs	0.7048 of 5 stars	$1.19 flat	N/A	-35.3%	$3.11M	$140K	N/A	20
HCWB HCW Biologics	3.2169 of 5 stars	$2.09 +7.7%	$5.00 +139.2%	-76.0%	$13.06M	$50K	N/A	40	Gap Up
ERNA Ernexa Therapeutics	2.2773 of 5 stars	$11.66 +4.7%	$30.00 +157.3%	-89.1%	$12.99M	$580K	N/A	10	News Coverage
SNGX Soligenix	2.4391 of 5 stars	$0.97 +12.3%	$6.00 +516.9%	-78.1%	$12.83M	$120K	N/A	20	News Coverage Gap Down
PHIO Phio Pharmaceuticals	3.0012 of 5 stars	$1.14 +3.6%	$14.00 +1,128.1%	-63.2%	$12.78M	N/A	N/A	10

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:VIVS) was last updated on 6/9/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

VivoSim Labs (VIVS) Competitors

VIVS vs. HCWB, ERNA, SNGX, PHIO, and KPRX

How does VivoSim Labs compare to HCW Biologics?

Summary

How does VivoSim Labs compare to Ernexa Therapeutics?

Summary

How does VivoSim Labs compare to Soligenix?

Summary

How does VivoSim Labs compare to Phio Pharmaceuticals?

Summary

How does VivoSim Labs compare to Kiora Pharmaceuticals?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

VIVS vs. The Competition

VivoSim Labs Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

VivoSim Labs (VIVS) Competitors

VIVS vs. HCWB, ERNA, SNGX, PHIO, and KPRX

How does VivoSim Labs compare to HCW Biologics?

Which has more risk & volatility, HCWB or VIVS?

Do insiders & institutionals believe in HCWB or VIVS?

Does the media favor HCWB or VIVS?

Do analysts recommend HCWB or VIVS?

Is HCWB or VIVS more profitable?

Which has higher valuation & earnings, HCWB or VIVS?

Summary

How does VivoSim Labs compare to Ernexa Therapeutics?

Which has higher earnings & valuation, ERNA or VIVS?

Do institutionals & insiders have more ownership in ERNA or VIVS?

Does the media refer more to ERNA or VIVS?

Do analysts prefer ERNA or VIVS?

Which has more risk and volatility, ERNA or VIVS?

Is ERNA or VIVS more profitable?

Summary

How does VivoSim Labs compare to Soligenix?

Which has more risk and volatility, SNGX or VIVS?

Do analysts rate SNGX or VIVS?

Which has better valuation & earnings, SNGX or VIVS?

Does the media favor SNGX or VIVS?

Is SNGX or VIVS more profitable?

Do insiders and institutionals hold more shares of SNGX or VIVS?

Summary

How does VivoSim Labs compare to Phio Pharmaceuticals?

Which has more risk & volatility, PHIO or VIVS?

Do insiders & institutionals have more ownership in PHIO or VIVS?

Is PHIO or VIVS more profitable?

Do analysts recommend PHIO or VIVS?

Which has stronger valuation & earnings, PHIO or VIVS?

Does the media prefer PHIO or VIVS?

Summary

How does VivoSim Labs compare to Kiora Pharmaceuticals?

Which has more risk & volatility, KPRX or VIVS?

Does the media refer more to KPRX or VIVS?

Is KPRX or VIVS more profitable?

Do insiders & institutionals hold more shares of KPRX or VIVS?

Which has better valuation & earnings, KPRX or VIVS?

Do analysts recommend KPRX or VIVS?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

VIVS vs. The Competition

VivoSim Labs Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools